Neuroblastoma screening: Difference between revisions
Jump to navigation
Jump to search
(Mahshid) |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}}{{HL}} | {{CMG}} {{AE}}{{HL}} | ||
==Overview== | ==Overview== | ||
There is insufficient evidence to recommend the routine screening for neuroblastoma as it has no mortality benefits. | |||
==Screening== | ==Screening== | ||
* There is insufficient evidence to recommend the routine screening for neuroblastoma by measuring the vanillylmandelic acid and homovanillic acid at 6 months or 1 year or age, as it does not have the mortality benefits.<ref name="US">Recommendations. US Preventive Services Task Force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=neuroblastoma Accessed on October, 5 2015</ref> | |||
==References== | ==References== | ||
Revision as of 16:16, 14 February 2019
|
Neuroblastoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Neuroblastoma screening On the Web |
|
American Roentgen Ray Society Images of Neuroblastoma screening |
|
Risk calculators and risk factors for Neuroblastoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
There is insufficient evidence to recommend the routine screening for neuroblastoma as it has no mortality benefits.
Screening
- There is insufficient evidence to recommend the routine screening for neuroblastoma by measuring the vanillylmandelic acid and homovanillic acid at 6 months or 1 year or age, as it does not have the mortality benefits.[1]
References
- ↑ Recommendations. US Preventive Services Task Force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=neuroblastoma Accessed on October, 5 2015